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Background: The PROTECT AF randomized trial compared Warfarin with left atrial appendage (LAA) closure using a filter device (WATCHMAN) in 
AF patients with CHADS2 ≥ 1. While the primary endpoint of stroke/systemic embolism/cardiovascular death favored LAA closure there were safety 
concerns about the procedure- predominantly procedure-related pericardial effusion and stroke (some of which may be operator dependent). We 
report the acute safety and the efficacy of this procedure in a high volume center involved in the study.
Methods: The analysis cohort included 10 patients randomized to LAA closure in the PROTECT AF trial and 62 patients enrolled in a subsequent 
non-randomized CAP registry (Continued Access PROTECT AF). The clinical success and the incidence of procedure related safety adverse events at 45 
days was assessed. All data were adjudicated by an independent Clinical Events Committee (CEC).
Results: The acute procedural success was 100%. Procedure-related complications were extremely low (table 1). Both acute success and safety 
profile were superior to the previously reported multi-center data of the PROTECT AF trial. There were no strokes in the device group.
Conclusion: This single center experience confirms a large volume per operator experience can yield a high procedural success with a very low 
complication rate.
Table 1. Success and safety of LAA occlusion
Number of patients 72
Average CHAD2 score 2.4
Implantation success 100%
Discontinuation of coumadin at 45 days 67/72 (93%)
Peri-procedural stroke 0
Pericardial effusion 1/72 (1%)
All cause stroke 0 in 67.1 patient years
